Motley Fool Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Motley Fool Asset Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.36M	Sell	70,651 -7,490	-10%	-$186K	0.09%	141
2026 Q1	$1.64M	Buy	78,141 +5,693	+8%	+$128K	0.07%	152
2025 Q4	$1.67M	Sell	72,448 -10,152	-12%	-$334K	0.06%	155
2025 Q3	$2.48M	Sell	82,600 -84,848	-51%	-$2.54M	0.1%	139
2025 Q2	$6.09M	Buy	167,448 +82,975	+98%	+$2.99M	0.28%	70
2025 Q1	$3.06M	Buy	84,473 +36,025	+74%	+$1.5M	0.17%	107
2024 Q4	$2.04M	Sell	48,448 -93,201	-66%	-$4.62M	0.11%	136
2024 Q3	$8M	Buy	141,649 +360	+0.3%	+$18.3K	0.47%	57
2024 Q2	$5.81M	Sell	141,289 -5,237	-4%	-$224K	0.39%	65
2024 Q1	$6.84M	Sell	146,526 -2,917	-2%	-$138K	0.44%	63
2023 Q4	$7.15M	Sell	149,443 -6,661	-4%	-$258K	0.53%	55
2023 Q3	$5.57M	Buy	156,104 +64,416	+70%	+$2.55M	0.45%	59
2023 Q2	$4.23M	Buy	91,688 +57,097	+165%	+$2.65M	0.38%	61
2023 Q1	$1.39M	Sell	34,591 -2,372	-6%	-$102K	0.15%	87
2022 Q4	$1.71M	Sell	36,963 -3,151	-8%	-$124K	0.19%	92
2022 Q3	$1.66M	Sell	40,114 -42,092	-51%	-$2.16M	0.16%	98
2022 Q2	$5.25M	Sell	82,206 -5,631	-6%	-$347K	0.49%	54
2022 Q1	$6.38M	Sell	87,837 -32,156	-27%	-$2.24M	0.47%	54
2021 Q4	$10.1M	Sell	119,993 -14,364	-11%	-$1.17M	0.65%	48
2021 Q3	$12.1M	Sell	134,357 -36,639	-21%	-$3.31M	0.79%	41
2021 Q2	$16.3M	Buy	170,996 +18,670	+12%	+$1.95M	1.08%	28
2021 Q1	$17.3M	Buy	152,326 +96,990	+175%	+$13.2M	1.25%	24
2020 Q4	$7.66M	Buy	55,336 +9,990	+22%	+$1.19M	0.57%	52
2020 Q3	$3.89M	Buy	45,346 +2,997	+7%	+$248K	0.35%	66
2020 Q2	$3.31M	Buy	42,349 +13,584	+47%	+$899K	0.33%	64
2020 Q1	$1.28M	Buy	+28,765	New	+$1.49M	0.17%	89

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Motley Fool Asset Management's RARE Position: Q2 2026 in Review

Motley Fool Asset Management reduced its Ultragenyx Pharmaceutical (RARE) stake by 9.6% in Q2 2026, selling an estimated $186K and leaving 70,651 shares worth $2.36M. The position accounts for 0.09% of the portfolio, ranked #141.

Motley Fool Asset Management first reported a position in RARE in Q1 2020 and has held it in 26 quarters since. The position peaked at $17.3M in Q1 2021. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

Motley Fool Asset Management held 70,651 shares of Ultragenyx Pharmaceutical worth $2.36M as of Q2 2026.
Motley Fool Asset Management sold 7,490 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $186K.
Ultragenyx Pharmaceutical made up 0.09% of Motley Fool Asset Management's portfolio in Q2 2026, its #141 holding.
Motley Fool Asset Management first reported a position in Ultragenyx Pharmaceutical in Q1 2020 and has held it in 26 quarters since.
Motley Fool Asset Management's Ultragenyx Pharmaceutical position peaked at $17.3M in Q1 2021.
311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Motley Fool Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.